Peginterferon alfa-2b + ribavirin

Drug Profile

Peginterferon alfa-2b + ribavirin

Alternative Names: Cotronak + peginterferon alfa-2b; PEG interferon-alpha-2b + ribavirin; PEG-Intron + REBETOL; PEG-Rebetron; Pegetron; Pegylated interferon-alpha-2b + ribavirin; Ribavirin + peginterferon alfa-2b; SCH-54031 + SCH-18908

Latest Information Update: 17 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antivirals; Interferons; Nucleosides
  • Mechanism of Action Enzyme inhibitors; Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 09 Apr 2015 Merck Sharp & Dohme terminates phase III trial in Hepatitis C (in type C compensated liver cirrhosis patients) in Japan (NCT00811967)
  • 17 Jul 2013 The UK's National Institute for Health and Care Excellence issues draft guidance recommending peginterferon alfa-2b in combination with ribavirin for Hepatitis C (in children, in adolescents)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top